Zacks Investment Research upgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) to Hold in a report released today.
- Updated: October 11, 2016
Only yesterday Meridian Bioscience, Inc. (NASDAQ:VIVO) traded -2.82% lower at $19.00. Meridian Bioscience, Inc.’s 50-day moving average is $19.31 and its 200-day moving average is $19.61. The last stock close price is down -3.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 158,247 shares of VIVO changing hands under the typical 189,242
Zacks Investment Research has upgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) to Hold in a report released on 10/11/2016.
Recent Performance Chart
Meridian Bioscience, Inc. has PE ratio of 22.56 with a one year low of $17.42 and a one year high of $21.49 and has a market capitalization of $0.
A total of 4 brokerages have released a report on Meridian Bioscience, Inc.. zero analysts rating the company a strong buy, two analysts rating the company a buy, three analysts rating the company a hold, two analysts rating the company a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $19.00.
Brief Synopsis On Meridian Bioscience, Inc. (NASDAQ:VIVO)
Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.